Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
757.920.01%
QQQ
707.600.15%
BTC/USD
76626.220.1201%
DIA
520.970.04%
GLD
395.500.22%
TLT
80.720.07%

Perspective Therapeutics Inc

CATXAMEX
Trade with Public
Trade with Public
$2.77
-0.22-7.36%
At close: Sep 10, 5:00 PM EST
$2.82
0.051.81%
After Hours: 4:57 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Perspective Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Perspective Therapeutics (CATX).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

13Buy
1Hold
Consensus RatingBuy# Analysts14Avg. Consensus PT$13Upside to Avg. PT+354.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$11
Aug 14, 2026B of A SecuritiesAlec StranahanPT CutNeutral$6→$5
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14

Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved